Molnupiravir capsules, a nucleoside analog, inhibit SARS-CoV-2 replication in early COVID-19 cases. Administered by pulmonologists in outpatient and community health centers. Supplied by biotech pharmaceutical companies to distributors for pandemic-era procurement demands.